Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cila Therapeutic Inc. operates within the Biotechnology & Pharmaceuticals technology area. The company's patent portfolio currently features 1 pending office action. This single action represents the current active engagement with the patent office for their pharmaceutical filings.
The prosecution is handled by 1 distinct examiner and 1 distinct art unit. This concentration indicates that the technical content remains within a single regulatory department. This allows for a focused prosecution strategy that accounts for the specific trends of 1 art unit.
STEVENS, MARK V is the busiest examiner, holding 1 busiest examiner pending office action. This examiner is responsible for the only active matter in the portfolio. The immediate success of the company's patent efforts is tied to the review and requirements of this specific individual.
The presence of 1 distinct examiner for 1 pending office action ensures a direct relationship between the examiner and the active workload. This consistency may lead to more predictable prosecution timelines. Practitioners can focus their efforts on the specific requirements of STEVENS, MARK V.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023686 | INHALABLE THERAPEUTIC AGENTS | STEVENS, MARK V | 88d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18023686 | INHALABLE THERAPEUTIC AGENTS | STEVENS, MARK V | 1613 | §103DP | Final Rejection | 88d overdue | Pending | Feb 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial